Sodium aminosalicylate controlled release - AGI Therapeutics

Drug Profile

Sodium aminosalicylate controlled release - AGI Therapeutics

Alternative Names: 4-ASA-Na - AGI Therapeutics; AGI-022

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AGI Therapeutics
  • Class Anti-inflammatories; Antituberculars; Salicylates; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • No development reported Ulcerative colitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in Ireland (PO, Controlled release)
  • 09 Feb 2009 Clinical development is ongoing in Ireland
  • 27 Sep 2007 Clinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top